GlassScriptPhysician profile
Joseph P Stevenson
NPI 1467444901
$222,255.16
in general payments reported to CMS, 2019-2025
47 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $16K · 2021: $26K · 2022: $22K · 2023: $40K · 2024: $58K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Travel and Lodging: $13K · Food and Beverage: $11K · Consulting Fee: $3,420 · Long Term Medical Supply Or Device Loan: $1,902 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,023.00 |
| Travel and Lodging | $13,332.71 |
| Food and Beverage | $10,929.80 |
| Consulting Fee | $3,420.00 |
| Long Term Medical Supply Or Device Loan | $1,902.22 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $90,381.53 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $52,903.51 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26,279.09 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $23,123.43 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $17,528.53 | 2021-2025 | Winrevair, Verquvo |
| Angiodynamics, INC. | $1,902.22 | 2024-2025 | Venacure 1470 Pro |
| Novartis Pharmaceuticals Corporation | $1,119.88 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,084.52 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $728.25 | 2019-2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $650.26 | 2019-2025 | |
| Novo Nordisk INC | $645.82 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $640.11 | 2019-2024 | Airsupra, Wainua, Farxiga |
| Pfizer INC. | $611.42 | 2019-2025 | |
| Boston Scientific Corporation | $425.71 | 2023-2025 | Watchman Flx, Rotapro, Impulse |
| Alnylam Pharmaceuticals INC. | $400.67 | 2021-2025 | Amvuttra, Onpattro |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $372.84 | 2019-2024 | Cardiomems, Jot Dx, Amplatzer Talisman |
| E.R. Squibb & Sons, L.L.C. | $368.49 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $367.18 | 2020-2025 | Nexletol |
| Amgen INC. | $354.94 | 2019-2025 | Repatha, Repatha |
| Glaxosmithkline, LLC. | $218.20 | 2021-2022 | |
| Irhythm Technologies, INC. | $205.06 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Amarin Pharma, INC. | $177.11 | 2019-2021 | |
| Medtronic, INC. | $158.70 | 2021-2023 | Reveal Linq, Azure Xt Dr Mri Surescan |
| Biotronik INC. | $146.71 | 2020-2024 | Biomonitor |
| Scpharmaceuticals INC. | $144.51 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $140.74 | 2019-2025 | Evkeeza |
| Bridgebio Pharma, INC. | $136.88 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $119.60 | 2020-2022 | |
| Akcea Therapeutics, INC. | $118.52 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.49 | 2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $106.52 | 2023-2024 | Inpefa |
| Biohaven Pharmaceuticals, INC. | $88.69 | 2021 | |
| Abiomed | $87.95 | 2021-2023 | Impella |
| Therapeuticsmd, INC. | $66.90 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $64.71 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $46.28 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Shockwave Medical, INC | $45.78 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Atricure, INC. | $42.63 | 2024-2025 | Atriclip Laa Exclusion System |
| Heartflow, INC. | $31.42 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $25.74 | 2023 | Arcalyst |
| Terumo Medical Corporation | $20.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.83 | 2021 | |
| Baxter Healthcare | $16.70 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Gilead Sciences, INC. | $14.36 | 2019 | |
| Amryt Pharma Holdings LTD | $12.28 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.